Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARCT NASDAQ:CRBP NASDAQ:FULC NASDAQ:TERN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARCTArcturus Therapeutics$17.19+2.9%$14.73$8.04▼$25.88$466.88M2.39472,062 shs370,996 shsCRBPCorbus Pharmaceuticals$9.85+1.1%$8.81$4.64▼$58.90$120.71M3.08182,062 shs153,927 shsFULCFulcrum Therapeutics$6.52+1.7%$7.07$2.32▼$9.30$352.67M2.82573,906 shs221,586 shsTERNTerns Pharmaceuticals$7.44-1.6%$5.72$1.87▼$11.40$651.07M-0.041.16 million shs1.04 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARCTArcturus Therapeutics-1.82%-4.79%+35.77%+36.22%-20.85%CRBPCorbus Pharmaceuticals+3.95%-2.89%+4.62%+14.99%-84.08%FULCFulcrum Therapeutics-1.08%-1.69%-6.15%-8.82%-25.03%TERNTerns Pharmaceuticals+8.62%+4.28%+38.21%+115.38%-0.79%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARCTArcturus Therapeutics2.7613 of 5 stars3.51.00.00.03.62.50.6CRBPCorbus Pharmaceuticals3.9062 of 5 stars3.62.00.04.72.21.70.0FULCFulcrum Therapeutics0.9678 of 5 stars2.31.00.00.02.41.70.0TERNTerns Pharmaceuticals3.9413 of 5 stars3.31.00.04.13.13.30.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARCTArcturus Therapeutics 3.00Buy$50.57194.19% UpsideCRBPCorbus Pharmaceuticals 3.10Buy$49.00397.46% UpsideFULCFulcrum Therapeutics 2.63Moderate Buy$7.5716.13% UpsideTERNTerns Pharmaceuticals 2.60Moderate Buy$15.63110.01% UpsideCurrent Analyst Ratings BreakdownLatest CRBP, TERN, ARCT, and FULC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/22/2025ARCTArcturus TherapeuticsLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$63.00 ➝ $54.008/12/2025ARCTArcturus TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$47.00 ➝ $49.008/12/2025ARCTArcturus TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$45.00 ➝ $42.008/6/2025CRBPCorbus PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$56.00 ➝ $53.007/30/2025CRBPCorbus PharmaceuticalsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy$28.007/30/2025FULCFulcrum TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Perform ➝ Sector Perform$4.00 ➝ $5.007/29/2025FULCFulcrum TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$4.00 ➝ $12.007/12/2025CRBPCorbus PharmaceuticalsLifesci CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy7/2/2025ARCTArcturus TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform7/2/2025ARCTArcturus TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Outperform ➝ Sector Outperform$32.00 ➝ $35.00(Data available from 9/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARCTArcturus Therapeutics$152.31M3.07N/AN/A$8.51 per share2.02CRBPCorbus PharmaceuticalsN/AN/AN/AN/A$9.06 per shareN/AFULCFulcrum Therapeutics$80M4.41N/AN/A$3.96 per share1.65TERNTerns PharmaceuticalsN/AN/AN/AN/A$3.49 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARCTArcturus Therapeutics-$80.94M-$2.23N/AN/AN/A-49.26%-24.87%-17.75%11/6/2025 (Estimated)CRBPCorbus Pharmaceuticals-$40.21M-$4.76N/AN/AN/AN/A-43.65%-39.62%11/6/2025 (Estimated)FULCFulcrum Therapeutics-$9.73M-$1.22N/AN/AN/AN/A-31.05%-28.96%11/12/2025 (Estimated)TERNTerns Pharmaceuticals-$88.85M-$1.04N/AN/AN/AN/A-27.35%-26.18%11/11/2025 (Estimated)Latest CRBP, TERN, ARCT, and FULC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025ARCTArcturus Therapeutics-$1.11-$0.34+$0.77-$0.34$17.64 million$28.30 million8/5/2025Q2 2025CRBPCorbus Pharmaceuticals-$1.55-$1.44+$0.11-$1.44N/AN/A8/5/2025Q2 2025TERNTerns Pharmaceuticals-$0.28-$0.26+$0.02-$0.26N/AN/A7/29/2025Q2 2025FULCFulcrum Therapeutics-$0.29-$0.28+$0.01-$0.28N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARCTArcturus TherapeuticsN/AN/AN/AN/AN/ACRBPCorbus PharmaceuticalsN/AN/AN/AN/AN/AFULCFulcrum TherapeuticsN/AN/AN/AN/AN/ATERNTerns PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARCTArcturus TherapeuticsN/A5.905.90CRBPCorbus PharmaceuticalsN/A9.219.21FULCFulcrum TherapeuticsN/A24.4224.42TERNTerns PharmaceuticalsN/A24.7024.70Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARCTArcturus Therapeutics94.54%CRBPCorbus Pharmaceuticals64.64%FULCFulcrum Therapeutics89.83%TERNTerns Pharmaceuticals98.26%Insider OwnershipCompanyInsider OwnershipARCTArcturus Therapeutics15.30%CRBPCorbus Pharmaceuticals3.60%FULCFulcrum Therapeutics7.00%TERNTerns Pharmaceuticals1.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARCTArcturus Therapeutics18027.16 million23.00 millionOptionableCRBPCorbus Pharmaceuticals4012.26 million11.77 millionOptionableFULCFulcrum Therapeutics10054.09 million50.31 millionOptionableTERNTerns Pharmaceuticals4087.51 million86.20 millionNot OptionableCRBP, TERN, ARCT, and FULC HeadlinesRecent News About These CompaniesDriehaus Capital Management LLC Has $2.11 Million Position in Terns Pharmaceuticals, Inc. $TERNSeptember 3 at 5:24 AM | marketbeat.comWellington Management Group LLP Increases Position in Terns Pharmaceuticals, Inc. $TERNSeptember 2 at 3:58 AM | marketbeat.comTerns Pharmaceuticals, Inc. $TERN Holdings Boosted by Walleye Capital LLCSeptember 1 at 4:24 AM | marketbeat.comNuveen LLC Purchases New Shares in Terns Pharmaceuticals, Inc. $TERNAugust 30, 2025 | marketbeat.comTerns Pharmaceuticals, Inc. (NASDAQ:TERN) Given Consensus Recommendation of "Moderate Buy" by BrokeragesAugust 30, 2025 | marketbeat.comWeight-Loss Wasteland: 5 Obesity Assets That FailedAugust 25, 2025 | biospace.comBTerns Pharmaceuticals to Host an Educational Webinar on TERN-701 for Investors in Advance of Phase 1 Data Expected in Fourth Quarter 2025August 21, 2025 | globenewswire.comDisappointing competitor oral GLP-1 data an opportunity for Terns, says MizuhoAugust 20, 2025 | msn.com5 Oral Obesity Drugs Challenging Lilly’s OrforglipronAugust 12, 2025 | biospace.comBWilliam Blair Has Positive Outlook of TERN FY2025 EarningsAugust 9, 2025 | marketbeat.comTerns Pharmaceuticals (NASDAQ:TERN) Releases Quarterly Earnings Results, Beats Expectations By $0.03 EPSAugust 6, 2025 | marketbeat.comTerns Seeks Partners for Metabolic Assets Amid Oversaturated Obesity MarketAugust 6, 2025 | biospace.comBTerns to stop funding metabolic disease trials beyond 2025, seeks partners for assetsAugust 6, 2025 | fiercebiotech.comFTerns (TERN) Q2 Net Loss Narrows 16%August 6, 2025 | fool.comTerns Pharmaceuticals Reports Q2 2025 Financial ResultsAugust 6, 2025 | tipranks.comTerns Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Corporate UpdatesAugust 5, 2025 | globenewswire.comTerns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)August 4, 2025 | globenewswire.comObesity in Focus: ADA Reveals R&D Priorities for Blockbusters-in-WaitingJuly 14, 2025 | biospace.comBTerns Pharmaceuticals CEO & Director Acquires 98% More StockJuly 4, 2025 | finance.yahoo.comTerns pharmaceuticals CEO Burroughs buys $90k in sharesJune 27, 2025 | investing.comRivus' weight loss drug scores MASH phase 2 win, showcases muscle-sparing potentialJune 26, 2025 | fiercebiotech.comFNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesHow Did Peter Thiel-Backed Crypto Exchange Bullish's IPO Go?By Jordan Chussler | August 14, 2025Tesla Is Balanced on a Knife Edge: Time to Tread CarefullyBy Sam Quirke | August 8, 2025Amazon’s Chart Just Flashed a Pennant Pattern—Here’s What to DoBy Sam Quirke | August 27, 2025Chevron Stock Outlook: Dividend Growth Meets InflationBy Chris Markoch | August 28, 2025How a Superstore Strategy Fueled MINISO’s 20% Stock SurgeBy Jeffrey Neal Johnson | August 26, 2025CRBP, TERN, ARCT, and FULC Company DescriptionsArcturus Therapeutics NASDAQ:ARCT$17.19 +0.49 (+2.93%) Closing price 04:00 PM EasternExtended Trading$17.13 -0.06 (-0.35%) As of 06:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.Corbus Pharmaceuticals NASDAQ:CRBP$9.85 +0.11 (+1.13%) Closing price 04:00 PM EasternExtended Trading$9.71 -0.14 (-1.42%) As of 07:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.Fulcrum Therapeutics NASDAQ:FULC$6.52 +0.11 (+1.72%) Closing price 04:00 PM EasternExtended Trading$6.52 0.00 (0.00%) As of 06:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Terns Pharmaceuticals NASDAQ:TERN$7.44 -0.12 (-1.59%) Closing price 04:00 PM EasternExtended Trading$7.45 +0.01 (+0.08%) As of 05:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of MASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Zscaler Shares Can Hit a Fresh High Before Year-End Why Qualcomm Is Outperforming NVIDIA After Months of Lagging Alphabet Stock Surges After Dodging Harsh Antitrust Remedies Wall Street Punishes Dell's Record Quarter: Why They Are Wrong Taiwan Semiconductor Falls on China News—Buy The Dip? CrowdStrike Tests $412 Support as Options Traders Turn Bullish What to Expect From the Q3 Reporting Season IREN Is Up 186% YTD on AI Pivot—And It’s Just Getting Started Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
